tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Mirum Pharmaceuticals assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Mirum Pharmaceuticals (MIRM) with a Buy rating and $73 price target Mirum is a biopharmaceutical company developing and commercializing therapies for the treatment of rare diseases, the analyst tells investors in a research note. The firm says that considering the growth potential of the current commercial products and the “”strong” pipeline potential, Mirum at its current market valuation of $2.2B is attractive to a long-term investor.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1